This bill aims to strengthen the Controlled Substances Act by scheduling specific synthetic compounds and expanding enforcement against emerging synthetic opioids. Its primary objectives include classifying certain substances as Schedule I and targeting the commercial distribution of dangerous new synthetic drugs. Specifically, the legislation amends the Controlled Substances Act to add synthetic 7-hydroxymitragynine and mitragynine pseudoindoxyl to Schedule I. However, it includes a crucial exemption for these substances when they occur naturally in kratom or finished kratom products, provided their concentrations do not exceed strict thresholds, such as 1 milligram per gram for solids or 1 milligram per milliliter for liquids. Any synthesized, concentrated, or isolated forms of these compounds are explicitly excluded from this exemption. Furthermore, the bill establishes a framework to treat " covered emerging synthetic opioids " as Schedule I controlled substances for enforcement purposes, specifically targeting their knowing or intentional manufacture, importation, exportation, and distribution. These covered opioids are defined by criteria including commercial distribution, greater potency than morphine, chemical synthesis, and lack of FDA approval. Importantly, the bill explicitly states that no person shall be subject to criminal or civil enforcement under this section based solely on the purchase, receipt, simple possession, or personal use of these emerging synthetic opioids, focusing enforcement on commercial suppliers.